CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
|
|
- Brian Lang
- 6 years ago
- Views:
Transcription
1 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma V10 Ratification date September 2016 Review date March 2018 Lead Author(s) Name Joanne Hamilton Dr M Hopkin Minesh Parbat Position within the Organisation Lead Nurse Respiratory DGNHFT GP & Respiratory Lead Prescribing Advisor Presented for discussion, approval and ratification to Core Policies and Procedures Group Change History Version Date Comments 1.0 September January September September 2010 Updates drug treatment Updates drug treatment and layout Updates drug treatment and layout Updates drug treatment and layout 5.0 July 2014 Updates drug treatment and layout 6.0 July 2015 Updates drug treatment and layout
2 7.0 September September 2015 September September 2016 Updates drug treatment and layout Updates drug treatment and layout (Draft) Final version 9.1 June 2017 Updates drug treatment and layout (Draft) 10.0 June 2017 Final version Link with Care Quality Commission Essential Standards of Quality & Safety Regulation 10, Outcome 16 Assessing & Monitoring the quality of services provision. Regulation13, Outcome 9 Management Of Medicines Link with Trust Purpose and Values statements These guidelines are aimed to improve the health and wellbeing of our local community. They link with values 1-11
3 Summary Sheet These treatment guidelines have been produced as a quick reference guide for HCPs who manage people with COPD. The guidelines are based on NICE COPD guidelines 2010 and GOLD COPD guidance These treatment guidelines will help to ensure appropriate, cost effective prescribing for people of all ages, with COPD The treatment guidelines will form part of an asthma education program. They support HCPs with prescribing and should be used in conjunction with the NICE/GOLD guidelines. These guidelines have been widely consulted on since March 2016, including: Dudley Respiratory Group Practice Nurse Mentors Prescribing and Medicines Management Team Presentations to Dudley GPs & Practice Nurses Nurse Consultant These guidelines will be reviewed at least every 2 years or sooner if indicated, by Dudley Respiratory Group or Area Clinical Effectiveness Committee.
4 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES DIAGNOSIS IS CONFIRMED USING POST BRONCHODILATOR SPIROMETRY RATIO (FEV 1 /FVC x 100) <70% FEV 1 % Predicted NICE 2010 GOLD % (+symptoms) MILD % MODERATE % SEVERE 3 <30% VERY SEVERE 4 A FULL CLINICAL HISTORY IS OF PARAMOUNT IMPORTANCE Choose a drug based on the person s symptomatic response and preference, the drug s side effects, potential to reduce exacerbations and cost. Do not use oral corticosteroid reversibility tests to identify patients who will benefit from inhaled corticosteroids. Be aware of the potential risk of developing side effects (including non-fatal pneumonia) in people with COPD treated with inhaled corticosteroids and be prepared to discuss with the patients consider osteoporosis risk see local guidance including FRAX score Ensure all patients have a personal management plan. Smoking cessation is the only intervention that reduces the decline of lung function in COPD. Encourage all patients to stop smoking. Encourage all patients to exercise. If the MRC is 3, or the patient considers themselves functionally disabled, refer to Pulmonary Rehabilitation. Steam Inhalation can prove beneficial Bronchodilators are the cornerstone of treatment for patients with COPD A B C D Low Risk Less Symptoms Low Risk More Symptoms High Risk Less Symptoms High Risk More Symptoms
5 INHALED THERAPY Adapted fom GOLD 2017 (A B C D) Always Check Compliance & Inhaler technique Assess Breathlessness using MRC and CAT score Prescribe by Brand INTERMITTENT BREATHLESSNESS AND/OR EXERCISE LIMITED Short Acting Bronchodilators or SABA SAMA BREATHLESSNESS and/or one exacerbation A B Long Acting Bronchodilators LAMA (STOP SAMA) or LABA or LAMA/LABA in a combination inhaler (STOP LAMA or LABA IN SEPARATE INHALERS) BREATHLESSNESS with 2 or more EXACERBATIONS C Long Acting Bronchodilators in a Combination Inhaler LAMA/LABA in a combination Inhaler BREATHLESSNESS with 2 or more EXACERBATIONS D Inhaled Corticosteroids LAMA/LABA in a combination Inhaler - (STOP LAMA OR LABA IN SEPARATE INHALERS) or LABA/ICS in a combination Inhaler plus a LAMA - (STOP LABA IN SEPARATE INHALER) When prescribing ICS for patients with COPD assess history of pneumonia and smoking status
6 Mucolytic Therapy Consider in people with a chronic productive cough and continue use if symptoms improve. Do not routinely use to prevent exacerbations. Carbocisteine capsules or oral liquid: 750mg three times a day for 4 weeks (capsules 375mg: Liquid 250mg/5mls) (If no benefit stop treatment). If beneficial continue with 750mg twice a day. Management of Acute Exacerbations Increase frequency of short acting Bronchodilators use & consider giving via a nebuliser Prednisolone 30mg once daily for 5-7 days Administer antibiotics in accordance with local guidelines (Hyperlink to Antibiotic Guidelines) Oxygen Therapy Assess the need for oxygen therapy Oxygen saturations less than 93% breathing air Refer as per local guidelines (Hyperlink to Oxygen Therapy) ORAL THERAPY (Hyperlink See for to osteoporosis Osteoporosis guidance Guidelines) Corticosteroids Maintenance use of oral corticosteroid therapy in COPD is not normally recommended Some people with advanced COPD may need maintenance oral corticosteroids if treatment cannot be stopped after an exacerbation. Keep the dose as low as possible, monitor for osteoporosis and offer prophylaxis. Theophylline - Prescribe by brand. Offer only after trials of short- and long-acting bronchodilators or to people who can not use inhaled therapy. Theophylline can be used in combination with beta2 agonists and muscarinic antagonists. Take care when prescribing to older people because of pharmacokinetics, comorbidities and interactions with other medications. Reduce Theophylline dose if macrolide or fluroquinolone antibiotics (or other drugs known to interact) are prescribed to treat an exacerbation.
7 ALWAYS OFFER PATIENTS ADVICE ON Smoking cessation Pulmonary rehabilitation Anxiety & depression Exercise Dietary advice KEY COPD SABA SAMA LABA LAMA ICS FEV 1 GOLD NICE CAT MRC Chronic Obstructive Pulmonary Disease Short Acting B 2 Agonist Short Acting Muscarinic Antagonist Long Acting Beta 2 Agonist Long Acting Muscarinic Antagonist Inhaled Corticosteroid Forced Expiratory Volume in the first second Global Initiative for Chronic Obstructive Lung Disease The National Institute for Health and Care Excellence COPD Assessment Tool Medical Research Council Breathlessness Score
8 COPD Inhaled Treatment - RECOMMENDED FIRST LINE PRESCRIBE BY BRAND Brand Name SABA LAMA LABA ICS Dosing Regime TDD ICS Short Acting Ventolin MDI 100mcgs Salbutamol 2 puffs as required Bronchodilators Salamol Easibreathe MDI 100mcgs Salbutamol 2 puffs as required Bricanyl Turbohaler 500mcgs Terbutaline 1 puff as required Salbutamol Easyhaler 100mcgs Salbutamol 2 puffs as required TDD BDP Equivalent Long Acting Eklira Genuair 322mcgs Aclidinium Bromide 1 puff twice daily Bronchodilators Spiriva Handihaler 18mcgs Tiotropium 1 puff once daily Formoterol EasyHaler 12mcgs Formoterol 1 puff twice daily Duaklir Genuair 340/12 mcgs Aclidinium Bromide Formoterol 1 puff twice daily Inhaled *Symbicort Turbohaler 400/12mcgs Formoterol Budesonide 1 puff twice daily 800mcgs 800mcgs Corticosteroids *Symbicort MDI 200/6 mcgs Formoterol Budesonide 2 puffs twice daily 800mcgs 800mcgs in a combination **Fostair NextHaler 100/6 mcgs Formoterol Beclometasone ExtraFine 2 puffs twice daily 400mcgs 1000mcgs inhaler (ICS+LABA) **Fostair MDI 100/6 mcgs Formoterol Beclometasone ExtraFine 2 puffs twice daily 400mcgs 1000mcgs *Symbicort is licensed in COPD FEV 1 <70% predicted **Fostair is licensed in COPD FEV 1 <50% predicted TDD Total Daily Dose BDP Beclometasone ICS Inhaled Corticosteroid LABA Long Acting Beta2 Agonist LAMA Long Acting Muscarinic Antagonist SAMA Short Acting Muscarinic Antagonist SABA Short Acting Beta2 Antagonist mcgs micrograms MDI Metered Dose Inhaler
9 COPD Inhaled Treatment - RECOMMENDED FIRST LINE PRESCRIBE BY BRAND Brand Name SABA LAMA LABA ICS Dosing Regime TDD ICS Short Acting Ventolin MDI 100mcgs Salbutamol 2 puffs as required Bronchodilators Salamol Easibreathe MDI 100mcgs Salbutamol 2 puffs as required Bricanyl Turbohaler 500mcgs Terbutaline 1 puff as required Salbutamol Easyhaler 100mcgs Salbutamol 2 puffs as required TDD BDP Equivalent Long Acting Eklira Genuair 322mcgs Aclidinium Bromide 1 puff twice daily Bronchodilators Spiriva Handihaler 18mcgs Tiotropium 1 puff once daily Formoterol EasyHaler 12mcgs Formoterol 1 puff twice daily Duaklir Genuair 340/12 mcgs Aclidinium Bromide Formoterol 1 puff twice daily Inhaled *Symbicort Turbohaler 400/12mcgs Formoterol Budesonide 1 puff twice daily 800mcgs 800mcgs Corticosteroids *Symbicort MDI 200/6 mcgs Formoterol Budesonide 2 puffs twice daily 800mcgs 800mcgs in a combination **Fostair NextHaler 100/6 mcgs Formoterol Beclometasone ExtraFine 2 puffs twice daily 400mcgs 1000mcgs inhaler (ICS+LABA) **Fostair MDI 100/6 mcgs Formoterol Beclometasone ExtraFine 2 puffs twice daily 400mcgs 1000mcgs *Symbicort is licensed in COPD FEV 1 <70% predicted **Fostair is licensed in COPD FEV 1 <50% predicted TDD Total Daily Dose BDP Beclometasone ICS Inhaled Corticosteroid LABA Long Acting Beta2 Agonist LAMA Long Acting Muscarinic Antagonist SAMA Short Acting Muscarinic Antagonist SABA Short Acting Beta2 Antagonist mcgs micrograms MDI Metered Dose Inhaler
10 Other Inhaled Treatment on the Formulary - SECOND LINE PRESCRIBE BY BRAND Brand Name SABA LAMA LABA ICS Dosing Regime TDD ICS Glycopyrronium Long Acting Seebri Breezhaler 44mcgs Bromide 1 puff once daily Bronchodilators Onbrez Breezhaler 150 & 300 mcgs Indacaterol 1 puff once daily Serevent Accuhaler 50mcgs Salmeterol 1 puff twice daily Serevent MDI 25mcgs Salmeterol 2 puffs twice daily TDD BDP Equivalent Inhaled Corticosteroids in a combination inhaler (ICS+LABA) Seretide Accuhaler 500/50 mcgs Relvar Ellipta 92/22 mcgs Existing Patients Only Fluticasone Propionate 1 puff twice daily 1000mcgs 2000mcgs Salmeterol Consultation Initiation Only Vilanterol Fluticasone Furoate 1 puff once daily 92mcgs?1000mcgs TDD Total Daily Dose BDP Beclometasone ICS Inhaled Corticosteroid LABA Long Acting Beta2 Agonist LAMA Long Acting Muscarinic Antagonist SAMA Short Acting Muscarinic Antagonist SABA Short Acting Beta2 Antagonist mcgs micrograms MDI Metered Dose Inhaler
Position within the Organisation
ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationCo. Durham & Darlington Respiratory Network COPD Treatment Guide
Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationRespiratory Inhalers. Identification Guide Version 3
Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationCHARM Guidelines for the diagnosis and
\ CHARM Guidelines for the diagnosis and management of COPD City and Hackney CCG Homerton University Hospital NHS Foundation Trust Written by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine,
More informationASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12
North Hampshire CCG Asthma Prescribing Guidelines June 2015 ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 These guidelines are based on the British Thoracic Society (BTS) and Scottish Intercollegiate
More informationCOPD Prescribing Guidelines
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
More informationCOPD RESOURCE PACK Section 5. Drug Treatment & Inhalers in Stable COPD
COPD RESOURCE PACK Section 5 Drug Treatment & Inhalers in Stable COPD In this section: 1. Links to Fife Formulary 2. Pharmacological Management of Stable COPD 3. How to use a Metered Dose Inhaler 4. How
More informationGMMMG COPD Formulary Inhaler Options October 2017
BNF 3.1.1 Adrenocepter agonists (SABA) Salbutamol Salbutamol Terbutaline Brand name Airsalb Ventolin Evohaler Bricanyl Turbohaler Device MDI MDI Dry powder Strengths 100 microgram 100 microgram 500 microgram
More informationDose. Route. Units. Given. Dose. Route. Units. Given
Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening
More informationMedicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version
More informationEvidence Review for Prescribing Clinical Network
Summary page Evidence Review for Prescribing Clinical Network Treatment: LABA/LAMA Combination devices in COPD Anoro Ellipta, Ultibro and Duaklir Genuair Prepared by: Noreen Devanney Topic Submitted by:
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationInclude patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more.
Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group rthampton General Hospital NHS Trust rthamptonshire Healthcare Foundation Trust Stepping down asthma
More information3. Respiratory System
1 3. Respiratory System Also see Appendix 3A Guidance on Management of Also see Appendix 3B Preferred Inhaler Devices for Adults Also see Appendix 3C Preferred Inhaler Devices for Adolescents (12-18 years)
More informationSummary of Lothian Joint Formulary Amendments
Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationChronic Obstructive Pulmonary Disease (COPD) Primary Care Guideline
Chronic Obstructive Pulmonary Disease (COPD) Primary Care Guideline For use across all Norfolk & Waveney CCGs Based on GOLD 2017 1, NICE CG101 COPD 2. Norfolk & Waveney Group In the UK in 2012, 29,776
More informationAsthma Treatment Guideline for Adults (aged 17 and over)
Asthma Treatment Guideline for Adults (aged 17 and over) Sharon Andrew MLCSU January 2019 (Review date 0 January 2022) VERSION CONTROL. Please access via the LMMG website to ensure that the correct version
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationReport generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number. Section.
Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ACLIDINIUM BROMIDE bronchodilators ADRENALINE/EPINEPHRINE
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review Date: December 2017 Bulletin 206 : DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendations
More informationChronic Obstructive Pulmonary Disease (COPD) Management
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Chronic Obstructive Pulmonary Disease (COPD) Management Diagnosis of COPD should be considered in patients over the age of 35 who have a risk factor (generally
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationTHEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE
I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management
More informationGreater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
More informationChapter 3: Respiratory System (7 th Edition)
Chapter 3: Respiratory System (7 th Edition) The Sheffield respiratory guidelines (April 2015) have been removed from the intranet. This is because the COPD section has been superseded by the COPD treatment
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationStepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs
Step Down guidance Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs Important Complete asthma control needs to be achieved for at least 12 weeks before attempting to step patients
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationRESPIRATORY INHALERS
RESPIRATORY INHALERS The correct administration of inhaled therapy is essential for successful, cost-effective and safe therapy. Everyone, including the patient needs to understand the importance of ensuring
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE Bulletin 218: September 2015 Review Date: September 2018 LAMA / LABA combination inhalers in COPD- Place in therapy review and choice of therapy JPC Recommendations:
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review date: December 2017 Bulletin 208 : Indacaterol + Glycopyrronium bromide 85/43 micrograms (Ultibro Breezhaler ) for the Treatment
More informationASTHMA TREATMENT GUIDE (ADULTS)
ASTHMA TREATMENT GUIDE (ADULTS) The BTS/SIGN guideline provides a wide range of information and guidance on the treatment of patients with asthma. https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/
More informationCOPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre
COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationApril 10 th, Bond Street, Toronto ON, M5B 1W8
Comprehensive Research Plan: Inhaled long-acting muscarinic antagonists (LAMAs; long-acting anticholinergics) for the treatment of chronic obstructive pulmonary disease (COPD) April 10 th, 2014 30 Bond
More informationCOPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy
Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic
More informationMedicines Management of Chronic Obstructive Pulmonary Disorder (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disorder (COPD) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (NHS Wandsworth) and Reena Rabheru-Dodhy (NHS Sutton & Merton) Date Prepared:
More informationWhy Asthma Still Kills The National Review of Asthma Deaths (NRAD)
APPROVED FINAL VERSION NHS Protect Why Asthma Still Kills The National Review of Asthma Deaths (NRAD) Summary of Recommendations for GP Practices and Community Pharmacies Author: Anne Henry Contact: anne.henry@nhs.net
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationBNF CHAPTER 3: RESPIRATORY
3.1 BRONCHODILATORS BNF CHAPTER 3: RESPIRATORY 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated (e.g., Easi-Breathe
More informationBetter Living with Obstructive Pulmonary Disease A Patient Guide
Better Living with Obstructive Pulmonary Disease A Patient Guide Second Edition November 2012 Queensland Health a Better Living with Chronic Obstructive Pulmonary Disease A Patient Guide is a joint project
More informationINHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop
INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers
More informationNHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group
NHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group Inhaler technique and respiratory conditions Guidance Sheet 16 When diagnosed
More informationAdult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred inhaler choices
ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred
More informationStepping down asthma treatment guidelines
Stepping down asthma treatment guidelines The potential for inhaled corticosteroids (ICS) to cause dose-related side-effects has led to asthma management guidelines recommending a dose reduction once asthma
More informationAdult Summary flowchart for Asthma Switch and Step Down to preferred inhaler choices
HVCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to preferred
More informationChronic Obstructive Pulmonary Disease (COPD) Guideline
Chronic Obstructive Pulmonary Disease (COPD) Guideline Unique ID: NHSL Author (s): Professor William MacNee, Dr. Gourab Choudhury. Lothian Respiratory (COPD) MCN Category/Level/Type: Level 2 Guideline
More informationCHARM ASTHMA TREATMENT GUIDELINE
NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE September 2015 Review Date: September 2018 Bulletin 219: Choice of Long Acting Muscarinic Agent (LAMA) inhaler for COPD JPC Recommendation: The availability
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report January 2018 Drug umeclidinium bromide (Incruse Ellipta) Indication Listing request Dosage form(s) Manufacturer Indicated for long-term, once daily maintenance
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
A F O C A l p O I N T l E A r N I N g p r O g r A m m E CHRONIC OBSTRUCTIVE PULMONARY DISEASE S E C O N D E D I T I O N BOOK 2 September 2013 FP120/2 CENTRE FOR PHARMACY POSTGRADUATE EDUCATION focal point
More informationumeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline
umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline 04 July 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationPATIENT INFORMATION Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet
PATIENT INFORMATION Chronic Obstructive Pulmonary Disease (COPD) Fact Sheet What is COPD? COPD is a general term, which includes the conditions chronic asthma, chronic bronchitis and emphysema. It is due
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More information500 micrograms/dose Turbohaler dry powder device 500 micrograms/ml injection. 12 micrograms/dose Turbohaler dry powder device
3.1 BRONCHODILATORS 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol Terbutaline 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated e.g. Easi-Breathe 200 micrograms/dose
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationHe is still Short of Breath Is there any new puffer? Saidul Ansary
He is still Short of Breath Is there any new puffer? Saidul Ansary Mr S C 66 yr. old retired Engineer for pre op elective assessment I am fine but Anaesthetist said I need to see you. I am little bit SOB,
More informationThese lung function tests involve you being seated and breathing into specialist equipment (like that shown below), via a filter and a mouthpiece.
Lung Function Tests This leaflet only gives you general information about the lung function (breathing) tests. However, it does not replace the need for the personal advice from the health care professional.
More informationRespiratory Inhaler Check-up Service
Respiratory Inhaler Check-up Service Dr Toby Capstick Lead Respiratory Pharmacist Leeds Teaching Hospitals NHS Trust toby.capstick@nhs.net 8 th May 2018 What is the Challenge? The Burden of Disease in
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationChronic Obstructive Pulmonary Disease (COPD)
NHS Eastern Cheshire Clinical Commissioning Group NHS South Cheshire Clinical Commissioning Group NHS Vale Royal Clinical Commissioning Group Mid Cheshire Hospitals NHS Foundation Trust East Cheshire NHS
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationSpirometry is a test that measures the size of your lungs and it also measures airflow in your lungs.
PATIENT INFORMATION This leaflet gives you general information about the lung function (breathing) tests. However, it does not replace the need for personal advice from the health care professional. Please
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationBulletin Independent prescribing information for NHS Wales
Bulletin Independent prescribing information for NHS Wales Respiratory disease September 2014 Respiratory diseases account for one in seven of all deaths in Wales the third largest cause of mortality for
More informationWhat is the Challenge?
Respiratory Inhaler Check-up Service What is the Challenge? Dr Toby Capstick Lead Respiratory Pharmacist Leeds Teaching Hospitals NHS Trust toby.capstick@nhs.net 25 th September 2018 The Burden of Disease
More informationMedical Directive. Activation Date: April 24, 2013 Review due by: December 1, Medical Director: Date: December 1, 2017
Medical Directive Pre and Post Bronchodilator Spirometry Testing and Treatment Initiation Assigned Number: Activation Date: April 24, 2013 Review due by: December 1, 2019 23 Approval Signature & Date Medical
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationAsthma Guidelines and Pharmacological Treatment. Dr James Wilkinson
Asthma Guidelines and Pharmacological Treatment Dr James Wilkinson Asthma is a common disease in the UK 5.4 million people in the UK are currently receiving treatment for asthma: 4.3 million adults (1
More informationCOPD 2016 What to do with all these New Inhalers?
COPD 2016 What to do with all these New Inhalers? Planning committee Content Experts Clinical reviewers Paul Hernandez MDCM FRCPC, Department of Respirology, QEII Health Sciences Centre, Associate Professor,
More informationOutline. EPIC Project. February EPIC Project. Diagnosis: Spirometry. Differentiation between COPD & Asthma
EPIC Project Enabling Patient health Improvements though COPD medicines optimisation Dr Toby Capstick Toby.capstick@nhs.net Outline Background on COPD COPD Assessment Cost Effective Treatment Medication
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationPocket Guide to Inhaler Technique A Step-By-Step Guide for Healthcare Professionals
Pocket Guide to Inhaler Technique A Step-By-Step Guide for Healthcare Professionals Endorsed by NHSGGC Respiratory Managed Clinical Network; June 2016 Designed by Medical Illustration Services Contents
More information